Table 4 Characteristics on patients with grade 3/4 late term effects (19 events in 18 patients). In all cases with grade 3/4 ulcers not healing during a 6 months period (n = 3, grey bars), ulcer persistence was found basing on tumor persistence (No 3,13, 16; data from these patient as well as of the 2 individuals with grade 3 xerostomia were excluded from this volumetric analysis (EA) of the 14 patients with grade 3/4 lesions).
From: IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients
Outcome | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Dg | TNM | Sequence | Grade 3/4 | t post RT (m) | Duration (m) | Treatment | NTR | Tumor | PTD | d/f SIB | Dmax G3/4 | GTV PT (cc) | PTV1 (cc) | cc>110% D |
1 | Cent oro | T3N2c | Prim | Ulcer | 4 | 7 | - | Healed | ANED | 66/54 | 2.2 | 75.7 | 56 | 213 | 0 |
2 | Supragl | T2N2b | Prim | Ulcer | 6 | 1 | - | Healed | ANED | 69.6/54 | 2.11 | 75.9 | 20.8 | 162.5 | 0 |
3 | Oral cav | T2N0 | Postop | Ulcer | 3 | 4 | 0 | Healed | ANED | 66/54 | 2 | 80.7 | 14 | 81.7 | 1.6 |
4 | Hypo | T4N1 | Prim | Ulcer | 3 | 3 | HBO | Healed | ANED | 66/54 | 2.2 | 75.8 | 74 | 299 | 0 |
5 | " | " | " | Larynx fibrosis | 10 | Persistent (30) | Tracheostoma | Tracheostoma | ANED | " | 2.2 | 75.8 | " | " | 0 |
6 | Hypo | T2N2b | Prim | Ulcer | 4 | 5 | - | Healed | ANED | 69.6/54 | 2.11 | 74.8 | 27 | 145 | 0 |
7 | Cent oro | T3N2b | Prim | Ulcer | 6 | 1 | - | Healed | ANED | 66/54 | 2.2 | 77.3 | 30 | 201 | 2 |
8 | Hypo | T2N2b | Prim | Ulcer | 6 | 2 | - | Healed | ANED | 69.6/54 | 2.11 | 76.8 | 34.5 | 220 | 2.2 |
9 | Cent oro | T3N0 | Prim | Ulcer | 4 | 3 | HBO | Healed | ANED | 66/54 | 2.2 | 77.3 | 29 | 77.7 | 7.7 |
10 | Lat oro | T3N2b | Postop | Ulcer | 2 | 3 | - | Healed | ANED | 65.4/54 | 2.11 | 72.8 | 7.8 | 212 | 0 |
11 | Cent oro | T3N2b | Prim | Bone | 4 | 6 | Surgery | Healed | ANED | 66/54 | 2.2 | 76.5 | 37.5 | 208 | 2 |
12 | Hypo | T3N0 | Prim | Dysphagia | 2 | ? (8) | Dilatation | Persistent | ANED | 69.6/54 | 2.11 | 75.7 | 32 | 149.5 | 0 |
13 | Hypo | T3N2c | Prim | Dysphagia | 5 | Persistent (14) | Dilatation | Persistent | ANED | 68.2/54 | 2.2 | 79.2 | 21.5 | 210 | 2.1 |
14 | Cent oro | T3N2b | Prim | Dysphagia | 5 | ? (9, lost) | - | ? | ANED | 69.6/54 | 2.11 | 76.7 | 24 | 113 | 0 |
15 | Oral cav | T2N2c | Prim | Ulcer | 3 | Persistent | - | Persistent | TU Persistent | 69.6/54 | 2.11 | EA | EA | EA | EA |
16 | Lat oro | T2N1 | Prim | Ulcer | 2 | Persistent | - | Persistent | TU Persistent | 69.6/54 | 2.11 | EA | EA | EA | EA |
17 | Cent oro | T3N2b | Prim | Bleeding ulcer | 0 | Persistent | Surgery | Persistent | TU Persistent | 69.6/54 | 2.11 | EA | EA | EA | EA |
18 | Hypo | T4N2a | Prim | Xerostomia | 0 | Persistent (14) | - | Persistent | ANED | 69.6/54 | 2.11 | EA | EA | EA | EA |
19 | Cent oro | T1N2b | postop | Xerostomia | 0 | Persistent (12) | - | Persistent | ANED | 64/54 | 2 | EA | EA | EA | EA |
Mean | 3.6 | 3.2 | 76.5 | 31.4 | 176.3 | 1.3 | |||||||||
Range | 0–10 | 1–7 | 2.0–2.20 | 72.8–80.7 | 2.5–37.5 | 78–299 | 0–7.7 | ||||||||